keyword
MENU ▼
Read by QxMD icon Read
search

Stage 4 colorectal cancer

keyword
https://www.readbyqxmd.com/read/29318692/promoter-hypermethylation-inactivate-tumour-suppressor-fam134b-and-is-associated-with-poor-prognosis-in-colorectal-cancer
#1
Farhadul Islam, Vinod Gopalan, Suja Pillai, Cu-Tai Lu, Kais Kasem, Alfred King-Yin Lam
The present study aims to examine promoter methylation status of FAM134B in a large cohort of patients with colorectal adenocarcinomas. The clinical significances and correlations of FAM134B promoter methylation with its expression are also analysed. Methylation-specific high-resolution melt-curve analysis followed by sequencing was used to identify FAM134B promoter methylation in colorectal adenomas (n=32), colorectal adenocarcinomas (n=164), matched adjacent non-neoplastic colorectal mucosae (n=83) and colon cancer cell lines (n=4)...
January 10, 2018: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/29306325/incidence-of-bone-metastases-in-patients-with-solid-tumors-analysis-of-oncology-electronic-medical-records-in-the-united-states
#2
Rohini K Hernandez, Sally W Wade, Adam Reich, Melissa Pirolli, Alexander Liede, Gary H Lyman
BACKGROUND: Bone metastases commonly occur in conjunction with solid tumors, and are associated with serious bone complications. Population-based estimates of bone metastasis incidence are limited, often based on autopsy data, and may not reflect current treatment patterns. METHODS: Electronic medical records (OSCER, Oncology Services Comprehensive Electronic Records, 569,000 patients, 52 US cancer centers) were used to identify patients ≥18 years with a solid tumor diagnosis recorded between 1/1/2004 and 12/31/2013, excluding patients with hematologic tumors or multiple primaries...
January 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29304818/proxy-and-patient-reports-of-health-related-quality-of-life-in-a-national-cancer-survey
#3
Jessica K Roydhouse, Roee Gutman, Nancy L Keating, Vincent Mor, Ira B Wilson
BACKGROUND: Proxy respondents are frequently used in surveys, including those assessing health-related quality of life (HRQOL). In cancer, most research involving proxies has been undertaken with paired proxy-patient populations, where proxy responses are compared to patient responses for the same individual. In these populations, proxy-patient differences are small and suggest proxy underestimation of patient HRQOL. In practice, however, proxy responses will only be used when patient responses are not available...
January 5, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29296176/predictive-value-of-different-proportion-of-lesion-hla-g-expression-in-colorectal-cancer
#4
Rui-Li Zhang, Xia Zhang, Shan-Shan Dong, Bing Hu, Qiu-Yue Han, Jian-Gang Zhang, Wen-Jun Zhou, Aifen Lin, Wei-Hua Yan
Differential expression of HLA-G has been observed among cancer types and tumors from individuals with the same type of cancer; however, its clinical significance is rather limited. In this study, expression and predictive relevance of HLA-G expression in 457 primary colorectal cancer (CRC, ncolon = 232, nrectal = 225) patients was investigated. Data showed 70.7% (323/457) of the CRC were HLA-G expression when the above 5% (HLA-GLow) was considered as positive, which wasn't associated with patient survival (p = 0...
December 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/29295878/understanding-comorbidity-profiles-and-their-effect-on-treatment-and-survival-in-patients-with-colorectal-cancer
#5
Erin E Hahn, Michael K Gould, Corrine E Munoz-Plaza, Janet S Lee, Carla Parry, Ernest Shen
Background: Patients with colorectal cancer (CRC) commonly present at an older age with multiple comorbid conditions and complex care needs at the time of diagnosis. Clusters of comorbid conditions, or profiles, have not been systematically identified in this patient population. This study aimed to identify clinically distinct comorbidity profiles in a large sample of patients with CRC from an integrated healthcare system, and to examine the effect of comorbidity profiles on treatment and survival. Methods: In this retrospective cohort study, we used latent class analysis (LCA) to identify comorbidity profiles in a sample of 7,803 patients with CRC diagnosed between 2008 and 2013...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29275313/tumor-infiltrating-lymphocytes-predict-the-chemotherapeutic-outcomes-in-patients-with-stage-iv-colorectal-cancer
#6
Masatsune Shibutani, Kiyoshi Maeda, Hisashi Nagahara, Tatsunari Fukuoka, Yasuhito Iseki, Shinji Matsutani, Shinichiro Kashiwagi, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: The anticancer immune response has been reported to contribute to the success of chemotherapy. The aim of this study was to evaluate the significance of the measurement of tumor-infiltrating lymphocytes (TILs) in the primary tumor using the method proposed by the International TILs Working Group as a prognostic marker of chemotherapeutic outcomes in patients with stage IV colorectal cancer (CRC). PATIENTS AND METHODS: A total of 57 patients with stage IV CRC who underwent palliative chemotherapy after resection of the primary tumor were enrolled...
January 2018: In Vivo
https://www.readbyqxmd.com/read/29237342/racial-ethnic-disparities-in-late-stage-colorectal-cancer-among-hispanics-and-non-hispanic-whites-of-new-mexico
#7
Melissa Gonzales, Fares Qeadan, Shiraz I Mishra, Ashwani Rajput, Richard M Hoffman
INTRODUCTION: Hispanics in New Mexico are diagnosed with more later-stage colorectal cancer (CRC) than non-Hispanic Whites (NHW). Our study evaluated the interaction of race/ethnicity and risk factors for later-stage III and IV CRC among patients in New Mexico. METHOD: CRC patients ages 30 to 75 years ( n = 163, 46% Hispanic) completed a survey on key explanatory clinical, lifestyle, preventive health, and demographic variables for CRC risk. Adjusted logistic regression models examined whether these variables differentially contributed to later-stage CRC among NHW versus Hispanics...
December 2017: Hispanic Health Care International: the Official Journal of the National Association of Hispanic Nurses
https://www.readbyqxmd.com/read/29233580/colorectal-carcinoma-in-the-frail-surgical-patient-implementation-of-a-work-area-focused-on-the-complex-surgical-patient-improves-postoperative-outcome
#8
Jordi Castellví Valls, Núria Borrell Brau, María José Bernat, Patricia Iglesias, Lluís Reig, Lluís Pascual, Marina Vendrell, Pilar Santos, Lorenzo Viso, Núria Farreres, Gonzalo Galofre, Carmen Deiros, Pedro Barrios
INTRODUCTION: Advanced age and comorbidity impact on post-operative morbi-mortality in the frail surgical patient. The aim of this study is to assess the impact of a comprehensive, multidisciplinary and individualized care delivered to the frail patient by implementation of a Work Area focused on the Complex Surgical Patient (CSPA). METHODS: Retrospective study with prospective data collection. Ninety one consecutive patients, classified as frail (ASAIII or IV, Barthel<80 and/or Pfeiffer>3) underwent curative radical surgery for colorectal carcinoma between 2013 and 2015...
December 9, 2017: Cirugía Española
https://www.readbyqxmd.com/read/29233486/cetuximab-combined-with-induction-oxaliplatin-and-capecitabine-followed-by-neoadjuvant-chemoradiation-for-locally-advanced-rectal-cancer-swog-0713
#9
Cynthia Gail Leichman, Shannon L McDonough, Stephen R Smalley, Kevin G Billingsley, Heinz-Josef Lenz, Matthew A Beldner, Aram F Hezel, Mario R Velasco, Katherine A Guthrie, Charles D Blanke, Howard S Hochster
BACKGROUND: Neoadjuvant chemoradiation (NCRT) is standard treatment for locally advanced rectal cancer. Pathologic complete response (pCR) has associated with improved survival. In modern phase III trials of NCRT, pCR ranges from 10% to 20%. Cetuximab improves response in KRAS (KRAS proto-oncogene) wild type (wt) metastatic colorectal cancer. S0713 was designed to assess improvement in pCR with additional use of cetuximab with induction chemotherapy and NCRT for locally advanced, KRAS-wt rectal cancer...
October 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29233113/clinicopathologic-and-endoscopic-features-of-early-stage-colorectal-serrated-adenocarcinoma
#10
Daiki Hirano, Shiro Oka, Shinji Tanaka, Kyoku Sumimoto, Yuki Ninomiya, Yuzuru Tamaru, Kenjiro Shigita, Nana Hayashi, Yuji Urabe, Yasuhiko Kitadai, Fumio Shimamoto, Koji Arihiro, Kazuaki Chayama
BACKGROUND: Serrated adenocarcinoma (SAC) is a distinct colorectal carcinoma variant that accounts for approximately 7.5% of all advanced colorectal carcinomas. While its prognosis is worse than conventional carcinoma, its early-stage clinicopathologic features are unclear. We therefore aimed to clarify the clinicopathologic and endoscopic characteristics of early-stage SACs. METHODS: Forty consecutive early-stage SAC patients at Hiroshima University Hospital were enrolled; SACs were classified into epithelial serration (Group A, n = 17) and non-epithelial serration (Group B, n = 23) groups...
December 12, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29204700/the-immunoscore-system-predicts-prognosis-after-liver-metastasectomy-in-colorectal-cancer-liver-metastases
#11
Yun Wang, Hao-Cheng Lin, Ma-Yan Huang, Qiong Shao, Zhi-Qiang Wang, Feng-Hua Wang, Yun-Fei Yuan, Bin-Kui Li, De-Shen Wang, Pei-Rong Ding, Gong Chen, Xiao-Jun Wu, Zhen-Hai Lu, Li-Ren Li, Zhi-Zhong Pan, Peng Sun, Shu-Mei Yan, De-Sen Wan, Rui-Hua Xu, Yu-Hong Li
BACKGROUND: The Immunoscore was initially established to evaluate the prognosis of stage I/II/III colorectal cancer patients. However, the feasibility of the Immunoscore for the prognosis of colorectal cancer liver metastases (CRCLM) has not been reported. METHODS: Liver metastases in 249 CRCLM patients were retrospectively analyzed. The Immunoscore was assessed according to the counts and densities of CD3+ and CD8+ T cells in the central- and peritumoral areas by immunohistochemistry...
December 4, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29203998/optimal-management-of-a-synchronous-diagnosis-of-phaeochromocytoma-and-colorectal-neoplasia
#12
Ridwaan Sohawon, Peter Truran, Jonathan Webster, Barney J Harrison, Sabapathy P Balasubramanian
The incidence rates of phaeochromocytoma and colorectal cancer (CRC) are approximately 1 and 65 per 100,000 per year, respectively. Simultaneous presentation of these conditions is rare and poses unique management challenges. We report on treatment strategies and clinical outcomes in a series of patients with colorectal neoplasia and phaeochromocytoma. Demographic and clinical details of four patients over a 4-year period were reviewed. The median (range) age at first presentation was 66 (52-70) years. Phaeochromocytoma (2...
December 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29203978/colorectal-cancer-in-india-an-audit-from-a-tertiary-center-in-a-low-prevalence-area
#13
Prachi S Patil, Avanish Saklani, Pravir Gambhire, Shaesta Mehta, Reena Engineer, Ashwin De'Souza, Supriya Chopra, Munita Bal
Colorectal cancer (CRC) is a common cancer worldwide with a low reported incidence in India. There is significant geographical variation in the incidence rates, and the presentation may also vary. There are few studies evaluating the clinical profile of CRC in Indian patients. We analyzed a prospective database maintained at the Tata Memorial Hospital, a referral cancer center in Mumbai, of consecutive patients with CRC between August 2013 and August 2014. We captured details regarding the demography, symptoms, pathology, stage, and treatment plan...
December 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29202108/kras-biomarker-testing-disparities-in-colorectal-cancer-patients-in-new-mexico
#14
Alissa Greenbaum, Charles Wiggins, Angela Lw Meisner, Manuel Rojo, Anita Y Kinney, Ashwani Rajput
Introduction: American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status. Methods: The New Mexico Tumor Registry (NMTR), a population-based cancer registry participating in the National Cancer Institute's Surveillance, Epidemiology and End Results program, was queried to identify all incident cases of CRC diagnosed among New Mexico residents from 2010 to 2013...
November 2017: Heliyon
https://www.readbyqxmd.com/read/29200873/clinical-application-of-carbon-nanoparticles-in-curative-resection-for-colorectal-carcinoma
#15
Li-Yu Wang, Jia-Huan Li, Xing Zhou, Qi-Chang Zheng, Xiang Cheng
Purpose: To explore the potential of carbon nanoparticles (CNs) for the intraoperative detection of positive and negative lymph nodes in the treatment of colorectal cancer. Patients and methods: The clinical data of 470 patients undergoing surgical procedures for colorectal cancer from June 2010 to February 2013 were analyzed retrospectively. The patients were divided into the CN group (183 males and 161 females; mean age, 58.6±12.4 years), who were given a CN suspension, and the control group (78 males and 48 females; mean age, 59...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29198632/prognostic-factors-predicting-survival-in-incurable-stage-iv-colorectal-cancer-patients-who-underwent-palliative-primary-tumor-resection-retrospective-cohort-study
#16
Min Sung Kim, Eun Jung Park, Jeonghyun Kang, Byung Soh Min, Kang Young Lee, Nam Kyu Kim, Seung Hyuk Baik
BACKGROUND: The aim of this study is to estimate prognostic factors predicting survival in patients with incurable stage IV colorectal cancer (CRC), who underwent palliative primary tumor resection (PTR) with chemotherapy. MATERIALS AND METHODS: We retrospectively performed an analysis using clinicopathological parameters of 103 patients with incurable stage IV CRC, who underwent palliative PTR with chemotherapy between 2006 and 2010. Prognostic factors associated with overall survival (OS) were evaluated by univariate and multivariate analyses...
November 30, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/29194915/factors-influencing-lymph-node-skip-metastasis-in-colorectal-cancer-a-retrospective-study
#17
Feng Bao, Zhi-Gang Deng, Dong Wang, Jian-Bo Xian-Yu, Guo-Qiang Li, Chun-Hua Xiang, Rong-Chao Xiang, Xing Zhi
BACKGROUND: The risk factors for lymph node skip metastasis (LNSM) have not been thoroughly clarified in patients with advanced colorectal cancer (CRC). This study aimed to identify the risk factors for LNSM in CRC patients who underwent laparoscopic radical resection with D3 lymphadenectomy. METHODS: This retrospective cohort study included a total of 167 consecutive patients who underwent laparoscopic radical resection with D3 lymphadenectomy for CRC between April 2005 and June 2017...
November 30, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/29190988/association-of-ezrin-expression-with-the-progression-and-prognosis-of-gastrointestinal-cancer-a-meta-analysis
#18
Feng Liang, Yangxin Wang, Ligen Shi, Jianmin Zhang
Background: Ezrin, a cytoskeletal protein, is involved in cell adhesion. Several studies have been performed to explore the association between Ezrin and gastrointestinal cancers, but the results are inconclusive. This meta-analysis aims to assess the prognostic value of Ezrin. Materials and Methods/Findings: PubMed and EMBASE were searched. Pooled hazard ratio (HR), odds ratio (OR) and 95% confidence intervals (CI) were utilized to evaluate the association between Ezrin expression and various clinical parameters...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29190919/molecular-characterization-of-pro-metastatic-functions-of-%C3%AE-4-integrin-in-colorectal-cancer
#19
Wanguang Zhang, Bixiang Zhang, Trung Vu, Guandou Yuan, Binhao Zhang, Xiaoping Chen, Upender Manne, Pran K Datta
The β4-integrin subunit has been implicated in development and progression of several epithelial tumor types. However, its role in metastases of colorectal cancer (CRC) remains elusive. To study CRC metastasis, we generated a highly invasive, metastatic cell line MC38-LM10 (LM10) by passaging mouse CRC MC38 cells ten times, using a splenic injection model of liver metastasis. Affymetrix microarray analyses of LM10 and MC38 cell lines and their corresponding liver metastases generated a gene signature for CRC metastasis...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29187884/a-single-nucleotide-polymorphism-in-hpgd-gene-is-associated-with-prostate-cancer-risk
#20
Xiaofei Qi, Yu Wang, Jianquan Hou, Yuhua Huang
Introduction: The HPGD gene was associated with some cancers, such as colorectal, breast, prostate, and bladder. However, detailed role of 15-hydroxyprostaglandin dehydrogenase (HPGD) gene remain unclear in prostate cancer. The study was to investigate the correlation between rs8752 that located in the 3'untranslated region (UTR) of the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene and prostate cancer (PCa) risk. Materials and Methods: 109 patients from the First Affiliate Hospital of Soochow University were recruited...
2017: Journal of Cancer
keyword
keyword
110220
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"